Although future studies including in vivo experiments are certainly warranted to fully characterize 8H8_SDIE, the data presented in this study underscore the potential of our B7-H3-targeting Fc-optimized mAb for sarcoma treatment. The gene discussed is CD276; the disease is sarcoma.